Novel Biology

Developing therapeutic antibodies targeting Siglec receptors

Lead Program Focused on Inhibiting Mast Cells

Inappropriately activated mast cells have been identified as key drivers in a number of inflammatory diseases


The Company’s most advanced antibody in clinical development is AK006. AK006 targets Siglec-6, an inhibitory receptor expressed on mast cells

Multiple Potential indications within Inflammation and Immunology

AK006 is currently being studied in Healthy Volunteers and Allakos plans to initiate a Phase 1 trial in patients with Chronic Spontaneous Urticaria (CSU) in Q2 2024

Chronic Spontaneous Urticaria

Symptoms of urticaria include severe itching, hives, and edema with episodic flares for many years